BAYER SUBMITS EU MARKETING APPLICATION FOR VEGF TRAP-EYE (ENG)
(The following press release from Bayer was received by e-mail. It was not confirmed by the sender.)
Not intended for U.S. and UK media Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema Following Central Retinal Vein Occlusion in EU
Berlin, December 6, 2012 - Bayer HealthCare and Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye (aflibercept solution for injection) for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO). VEGF Trap-Eye has already been approved under the brand name EYLEA® in the United States, Europe, Japan, Australia, and in several other countries for the treatment of wet age-related macular degeneration (wAMD).
"We are delighted to announce the filing for VEGF Trap-Eye for the treatment of macular edema following CRVO indication with the European Medicines Agency (EMA), so shortly after receiving approval for EYLEA for the treatment of wet AMD," said Kemal Malik, M.D., member of the Bayer HealthCare Executive Committee and Head of Global Development. "With the 52 week results of two Phase III trials showing substantial and sustained improvement in vision relative to the sham control group, we are confident that VEGF Trap-Eye has the potential to provide patients and physicians a new treatment option for macular edema following CRVO."
The submission of VEGF Trap-Eye for macular edema following CRVO is based on data from the Phase III COPERNICUS and GALILEO studies. In both studies, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters - measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart - of Best Corrected Visual Acuity (BCVA) at 24 weeks compared to baseline on the ETDRS visual acuity charts. The VEGF Trap-Eye 2 milligrams (mg) monthly group was significantly superior to the sham control group for the primary endpoint. The effects were largely maintained until week 52.
The week 52 results of the GALILEO and COPERNICUS studies demonstrated an acceptable safety profile for VEGF Trap-Eye.
EYLEA was approved in the United States for the treatment of wet AMD in November 2011 and for macular edema following CRVO in September 2012. EYLEA was also approved in Europe, Japan, Australia, and in several other countries earlier this year for use in wet AMD.
Phase III trials are currently under way with VEGF Trap-Eye in the treatment of diabetic macular edema (DME) and myopic choroidal neovascularization (mCNV).
Bayer HealthCare and Regeneron are collaborating on the global development of VEGF Trap-Eye. Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States. Bayer HealthCare licensed the exclusive marketing rights outside the United States, where the companies will share equally the profits from any future sales of VEGF Trap-Eye, except for Japan where Regeneron will receive a royalty on net sales.
About VEGF Trap-Eye (aflibercept solution for injection) VEGF Trap-Eye is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. VEGF Trap-Eye acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF) and thereby can inhibit the binding and activation of these cognate VEGF receptors. VEGF Trap-Eye is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.
About Central Retinal Vein Occlusion (CRVO) Over 100,000 people in the United States and more than 66,000 people in major European countries are estimated to suffer from CRVO. CRVO is caused by obstruction of the central retinal vein that leads to a back up of blood and fluid in the retina. The fluid can result in retinal injury and loss of vision. VEGF levels are elevated in response to this retinal injury contributing to macular edema. It is believed that anti-VEGF treatment may help decrease vascular permeability and edema.
About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use, ZALTRAP is co-commercialized with Sanofi. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at http://www.regeneron.com.
About Bayer HealthCare The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. More information at http://www.healthcare.bayer.com.
Our online press service is just a click away: http://press.healthcare.bayer.com
Find more information at http://www.bayerpharma.com.
Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
This press release is available here: http://www.baynews.bayer.de/baynews/baynews.nsf/id/2012-0521-e
Yours BayNews Editorial Team
Bayer AG Communications Building W11 51368 Leverkusen, Germany
Further news releases you can find here: http://www.press.bayer.com